Patent for License:

Nanotechnology for controlled drug release: Core-shell nanoparticles for sustained release of drug molecules    

A sustained release, core-shell structure, cytokine-containing bionanocomposite.

Overview

Summary

Our partner, University of Szeged has developed a core-shell nanoparticle technology aimed to be used in controlled drug release. The R&D phase of development is finished for protein drugs; additional research is under way for oligonucleotide drugs. Our client is looking for investors, who would be interested in co-financing the research and the preclinical phase.


Innovation and main advantages of the technology

The invention is a novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds, which provides a relatively easy and inexpensive way to formulate sustained release products. The solid cores of the nanoparticles are prepared by first precipitation with salts, then they are subsequently coated with polyelectrolyte multilayers using the electrostatic self-assembly (ESA) method, or in other words, the layer-by-layer self-assembly. Pharmacokinetic studies in rabbit models detected steady INF release for 10 days after subcutaneous injection administration of the nanointerferon formulation.

Benefits:

- Provides a relatively easy method
- Provides a relatively inexpensive method
- Particles are in the nano size range
- Benefits of sustained release for patients (avoiding sudden large concentration, rare dosage, improved effects and comfort)
- Economical (the installation of the protein drug is more efficient than the infiltration methodeconomical)

Primary Application of the Technology

Pharmaceutical application: controlled drug release

The Problem Solved by the Technology

Formulating biologically active proteins (e.g. enzymes, hormones, and cytokines) as drugs poses a number of specific problems related to the preservation of biological activity through the conservation of higher order protein structures. In addition to their primary structure, the secondary, tertiary and quaternary structures of the proteins are prerequisites for biological function. Thus, sufficiently mild conditions are required to ensure the stability of not only the primary, but also the higher structures against irreversible conformational changes. Other issues are also known to be tied to bioactive protein formulations, such as sustained release, stability and complete release of a drug.

Competitive Advantage

- Provides a relatively easy method
- Provides a relatively inexpensive method
- Particles are in the nano size range
- Benefits of sustained release for patients (avoiding sudden large concentration, rare dosage, improved effects and comfort)
- Economical (the installation of the protein drug is more efficient than the infiltration methodeconomical)

Additional Information

Stage of development: The next steps are testing the formulation of oligonucleotide molecules, and starting toxicology and efficacy studies.

Our client is looking for investors, who would be interested in co-financing the research and the preclinical phase.